Allergy Asthma Immunol. Since viral levels during early infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) tend to be highest in the nose and nasopharynx 1, a nasal spray with an active substance . A pilot study of 0.4% povidone-iodine nasal spray to eradicate SARS-CoV-2 in the nasopharynx. What the science says, Racial inequalities deepened in US prisons during COVID, The WHO at 75: what doesnt kill you makes you stronger, White House to tap cancer leader Monica Bertagnolli as new NIH director, Massive mosquito factory in Brazil aims to halt dengue, Seeks to identify an outstanding Scientific Director to lead its Division of Preclinical Innovation (DPI) in Rockville, Maryland. COVID-19 Get the latest information from the CDC about COVID-19. Scientific Reports (Sci Rep) The product targets a stable site on the spike protein of the virus that is not known to mutate. Pawar, R. D. et al. Moreover, this group showed that azelastine has the potential to inhibit SARS-CoV-2 cell entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and to inhibit intracellular virus replication through binding to the sigma-1 receptor6. The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19? B.R. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Both have the allure of being variant-proof, Topol added., Many laboratories are shifting from treatments using monoclonal antibodies to treatments using smaller antibody fragments called "nanobodies" because they are more cost-effective and are able to last longer in storage, Mkel and colleagues noted., Several of these nanobodies have shown promise against viruses in cell culture or animal models, including as an intranasal preventive treatment for SARS-CoV-2.. We are aware that this limited the capture of COVID-19 specific issues as questions were not specifically aimed for COVID-19 patients. The first administration of the nasal spray was carried out in the presence of the investigator; products were subsequently self-administered for 11days (treatment phase). Boots cold and flu nasal spray that costs just 6 could stop - The Sun https://doi.org/10.1016/j.jinf.2021.05.009 (2021). It's a type of antibody that targets the coronavirus' spike protein. https://doi.org/10.1038/s41591-022-01780-9 (2022). Indeed, the majority of the study subjects carried this variant. Researchers found that for people who regularly used a prescription corticosteroid like Beconase or Nasonex before getting sick with COVID-19, the risk of severe outcomes like hospitalization and death dropped by as much as 25%. . Of note, we cannot rule out the possibility that the placebo (nasal spray buffer) contributed to viral clearance. This observational study (HUN-VE: Hungarian Vaccine Effectiveness) estimated vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related mortality in 3.7 million . 76, 469475. Emerg. The nasal spray is comprised of xylitol and GSE (Grapefruit Seed extract) which provides antibacterial properties as well as preventing viral adhesion in the nasal passage. COVID-19 nasal sprays may one day prevent and treat infection - ABC This way, the virus moves on.. 1). For male patients, the assessment was done via phone call. and JavaScript. Monoclonal antibodies can block SARS-CoV-2 from . Download PDF Copy. Comirnaty is the FDA-approved monovalent COVID-19 (coronavirus 2019) vaccine made by Pfizer for BioNTech. and JavaScript. The reduction in virus load over the entire treatment period was clinically meaningful for all three groups (p<0.0001 for both genes). A., Dion, S. P., Buchholz, D. W., Imbiakha, B., Olmstead, A. D., Jager, M., Dsilets, A., Gao, G., Martins, M., Vandal, T., Thompson, C. A. H., Chin, A., Rees, W. D., Steiner, T., Nabi, I. R., Marsault, E., Sahler, J., Diel, D. G., . Z. Gesundheitswissenschaften J. At the end of the study, patients and investigators assessed the overall tolerability and efficacy of the treatment as very good (3), good (2), moderate (1) or poor (0). Only one of the 20 mice given saline survived. Correspondence to J. Ghahremanpour, M. M. et al. performed the statistical analysis. The reduction of the symptom score from baseline to day 11 was 8.389.42 in the 0.02% azelastine group and 11.129.45 in the placebo group. (2021) COVID-19: Azelastine nasal spray reduces virus-load in nasal swabs (CARVIN). Internet Explorer). https://cornellsun.com/2022/04/27/cornell-research-team-to-develop-covid-19-nose-spray-treatment/, https://doi.org/10.1038/s41586-022-04661-w, Antiviral Nasal Spray Shows Promise Fighting COVID-19. Recent publications indicating that in vitro infectivity correlates with high virus concentrations (Ct25) in nasal swabs28,29,30 underline the importance of analysis of this subset population. SARS-CoV-2 viral load predicts COVID-19 mortality. Boots nasal spray containing seaweed could fight Covid-19 HG, MS, and FK declare no conflict of interest. Pediatr. Whether the current data can be extrapolated to other SARS-CoV-2 variants needs to be investigated. Patient reported outcomes were documented by patient diaries and questionnaires. Prevention is the best medicine, and COVID-19 vaccines block most SARS-CoV-2 infections. It also appears to work as a treatment if used within 4 hours after infection inside the nose, new research reveals., Known as TriSb92(brand name Covidin, from drugmaker Pandemblock Oy in Finland), the viral inhibitoralso appears effective against all coronavirus variants of concern, neutralizing even the Omicron variants BA.5, XBB, and BQ.1.1 in laboratory and mice studies., Unlike a COVID vaccine that boosts a persons immune system as protection, the antiviral nasal spray works more directly by blocking the virus, acting as a "biological mask in the nasal cavity," according to the biotechnology company set up to develop the treatment.. Chavda, V. P., Baviskar, K. P., Vaghela, D. A., Raut, S. S. & Bedse, A. P. (2023) Nasal sprays for treating COVID-19: A scientific note. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11days, during which viral loads were assessed by quantitative PCR. Sign up for the Nature Briefing newsletter what matters in science, free to your inbox daily. Nature 605, 340348 (2022). The most promising compound, N-0385, virtually stopped infection in its tracks. https://doi.org/10.1016/s1081-1206(10)63465-5 (1996). Get the most important science stories of the day, free in your inbox. Can Nasal Sprays Treat or Prevent COVID-19? - GoodRx Patients were assigned a treatment number in an ascending mode according to their chronological order of inclusion. Kim, M.-C. et al. The reduction in the symptom score was clinically relevant for all three groups. PubMed Central Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, Pandya D, Menachery VD, Rahman S, Cao . These nanobodies and TriSb92 target a specific part of the coronavirus spike protein called the receptor-binding domain (RBD). Jain, R. & Mujwar, S. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. The shown effects of azelastine nasal spray may thus be suggestive of azelastines potential as an antiviral treatment. While PCR results in the placebo group turned negative only on day 11 of treatment, individual patients of the 0.1% azelastine group already showed negative PCR test results from day 2 on. The overall AUC of the Azelastine 0.1% group (red area) was significantly greater than that of placebo (green area), p=0.007. Anna R. Mkel, PhD, senior scientist, Department of Virology, University of Helsinki, Finland. In addition, intervals between swab sampling were short and the overall number of performed PCR tests was high to allow a very close determination of the viral clearance. Boots Dual Defence Nasal Spray is used to dampen the symptoms of cold and flu. Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml 20.00 Save 3.96 Worth 23.96 when bought separately 1486004 Maximum quantity reached Add to basket Add to favourites Collect 80 Boots Advantage Card points with this purchase Product details In this bundle: Bioinformation 16, 236244. Klussmann, J.P., Grosheva, M., Meiser, P. et al. Of note, the mean viral load value showed small variability, thereby supporting the power of the current study. Marshall, J. C. A minimal common outcome measure set for COVID-19 clinical research. https://doi.org/10.7554/eLife.69302 (2021). Therefore, the primary analysis for the viral loads was conducted non-parametrically. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Our study showed both strengths and limitations. PubMed This trial was conducted at the Department of Otorhinolaryngology, Head and Neck Surgery of the Faculty of Medicine of the University of Cologne, Germany. In animal models, by directly inactivating the virus,TriSb92 offers immediate and robust protection against coronavirus infection and severe COVID, said Anna R. Mkel, PhD, lead author of the study and a senior scientist in the Department of Virology at the University of Helsinki in Finland., Thestudy was published online March 24 in Nature Communications.. It also appears to . 17(2), 19. 15, 75297536. Components are mixed from two chambers to create the final NO-producing formulation. Google Scholar. 10, 294. https://doi.org/10.3389/fphar.2019.00294 (2019). Pharmaceutics 14, 2502. https://doi.org/10.3390/pharmaceutics14112502 (2022). Although it may be expected that the azelastine might be most efficacious during very early time points after infection, its application in the current study setting could only be started during the symptomatic phase of the disease. 20, e192e197. 62, 50937, Cologne, Germany, Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. Three-group comparisons were analysed with KruskalWallis test. 13, 861295. https://doi.org/10.3389/fphar.2022.861295 (2022). Nature 602, 676681. The trial protocol and the data are however available from the authors upon reasonable request and with permission of URSAPHARM Arzneimittel GmbH. Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. Comirnaty is FDA-approved as a 2-dose series for the prevention of COVID-19 in individuals 12 years of age and older. In a subset of patients (initial Ct<25) viral load was strongly reduced on day 4 in the 0.1% group compared to placebo (p=0.005). Boots UK - Swansea University Research Study of NHS Frontline Workers Infect. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany is the sponsor of the clinical trial. Multinomial regression analysis was done to 26 determine the association between nasal carriage of Bacillus and COVID-19 severity after 27 adjusting for age, sex, and co-morbidity status. https://doi.org/10.1001/jama.2021.0202 (2021). Subgroups were analysed exploratorily (e.g., subgroups regarding gender, age, symptom severity, etc.). Cegolon, L. et al. Jean, F. (2022). Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients. Because N-0385 was suitable for use as a nasal spray, researchers used a mouse model that develops severe COVID-19 and gave the mice either N-0385 or control doses of saline in their noses. Quality of life was assessed with the SF-36 questionnaire as no COVID-19 specific patient-reported outcome measures were available at the time of study. By blocking that access, compounds that target TMPRSS2 have the potential to be effective against both current and future variants. Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. https://doi.org/10.6026/97320630016236 (2020). EN, VS and GN are shareholders in CEBINA GmbH, RK and EN are inventors on related patent applications. JPK and CL have received grants from the sponsor URSAPHARM Arzneimittel GmbH for performing this trial. Following sampling, swabs were placed into 3mL Virus Transport Medium (VTM, Biocomma) and delivered to the laboratory as quickly as possible. P.A.de.A., H.M. and H.A.S. Categorical data were described by absolute frequencies and percentage of valid cases. Marinomed plans a clinical trial with Carragelose nasal spray as COVID If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. The most common COVID-19 symptoms (loss of sense of smell, loss of taste, fever, cough, and coryza) improved over time in all 3 treatment groups; and no statistical differences were observed between groups. Chem. The improvement of the symptom shortness of breath was significantly greater on days 3 (p=0.004) and 4 (p=0.011) in the 0.1% azelastine group compared to placebo (supplementary Figure S3). Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. Intern. Article TriSb92 isone of multiple nasal spray approaches but unlikely to be as durable as effective nasal vaccines, saidEricTopol, MD, a professor of molecular medicine and executive vice president of Scripps Research in La Jolla, CA. Of those, 81 patients belonged to the Intention-To-Treat (ITT) population, comprising randomised patients meeting the key eligibility criteria and having evaluable viral load data on day 1 (baseline) and on day 11 (end of treatment). Ethics approval was granted by the Ethics Committee of the Faculty of Medicine of Cologne University on the 10th of February 2021. Decreases of viral load were also reflected in increases of negative PCR results over time. What scientists say. was the principal investigator responsible for the conduct of the study, M.G. Data was analysed primarily exploratively; there was no formal testing of a given hypothesis. Antiviral efficacy was observed at an EC50 of~6M, which is an approximately 400-fold lower concentration compared to commercially available azelastine nasal sprays. the epithelium, to recreate the first line of defense against respiratory viruses. March 31, 2023 An antiviral therapy in early development has the potential to prevent COVID-19 infections when given as a nasal spray as little as 4 hours before exposure. Researchers supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) have developed a nasal spray that has the potential to not only treat COVID-19 but also prevent SARS-CoV-2 infection in a way that the virus cant mutate to avoid. Researchers have looked for ways to prevent SARS-CoV-2 infection that the virus cant learn to dodge or evade by mutating. All tests were performed two-sided and the type 1 error () was set to 5%. Samples of day 1 represent pre-treatment baseline samples. One study of about 400 health-care workers suggests a nasal spray may reduce the incidence of COVID-19 by up to 80 per cent. ICE-COVID a randomised, double blind, placebo-controlled phase III trial of the prophylactic efficacy of iota-carrageenan nasal and throat spray in preventing COVID-19 illness in at risk healthcare professionals. Assignment of the treatment with the investigational medicinal product in the different doses vs. placebo to each treatment number was performed in a centrally conducted, computer-generated 1:1:1 randomization procedure. All this made her work personal: for the past decade, Moscona, a molecular virologist, had been hunting for compounds that could stop viruses in their tracks, before the pathogens infect even a single cell in a persons body. Overall, none of the participating patients had clinically relevant increased values of body temperature (data not shown). Thus, antibody therapy (bamlanivimab and etesevimab) in positively tested, non-hospitalized patients demonstrated that treatment resulted in decreased SARS-CoV-2 viral load by log100.57 on day 11, which was significantly greater compared to placebo (p=0.01)33. If all goes well, the hope is that we'll have a safe and effective nasal spray to serve as an extra line of defense in the fight against COVID-19. ICE-COVID, will investigate whether Dual Defence can either prevent Covid-19 infection or reduce . Inhibition of SARS-CoV-2 by bentonite-based nasal spray. Various studies have looked at the role of different foods in preventing coronavirus infection severe Covid-19 These include seaweed and grapefruit-based nasal sprays, dark chocolate, tuna. J. During visits, nasopharyngeal swabs were taken for quantitative PCR measurements, and investigators assessed the patient status in accordance with the WHO clinical progression scale11. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Comirnaty may help your body develop immunity to SARS-CoV-2, the virus that causes COVID-19. Suitable for Watts, A. M., Cripps, A. W., West, N. P. & Cox, A. J. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Early negativization of SARS-CoV-2 infection by nasal spray of seawater plus additives: The RENAISSANCE open-label controlled clinical trial. The aim of our study was to support the preclinical evidence for azelastines antiviral activity in patients tested positive for SARS-CoV-2. Bullinger, M., Kirchberger, I. Anti. CAS Article Detection of the alpha (B.1.1.7) variant was based on single nucleotide polymorphism analysis for SARS-CoV-2 spike gene mutation N501Y and deletion H69/V70. The RBD is where the coronavirus attaches to cells in the body. Assuming a pooled standard deviation of =3 units, a two-sided =0.05 and a power of 90%, a sample size of 23 patients per treatment group was calculated. were involved in data management. A closer look at single symptoms confirmed moderate expression of symptoms (supplementary Figure S1) and the general decrease of symptoms over time (supplementary Figure S2). A., Dion, S. P., Buchholz, D. W., Imbiakha, B., Olmstead, A. D., Jager, M., Dsilets, A., Gao, G., Martins, M., Vandal, T., Thompson, C. A. H., Chin, A., Rees, W. D., Steiner, T., Nabi, I. R., Marsault, E., Sahler, J., Diel, D. G., . Loading Twitter content. In a study examining the effect of azelastine nasal spray on upper respiratory infections in children, it was found that the placebo group, receiving hypertonic saline solution (twice daily) also produced a favourable response compared to those receiving no treatment31. On Day 8, 5 of the 27 (18.5%) and 6 of the 28 (21.4%) patients in the 0.1% azelastine and 0.02% azelastine groups, respectively were negative for the ORF1a/b gene, compared to the 0 of 26 patients in the placebo group. Carrouel, F. et al. EudraCT number: 2020-005544-34. Treatment kits were manufactured by URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany, according to the randomization list (as sequentially numbered containers). Wiesmller (health authorities Cologne, Germany) for his support regarding regulatory issues, PD Dr. E. Raskopf for editorial assistance, and H. Papp for her assistance in PCR control experiments. A newly discovered small molecule could be sprayed into people's noses to prevent COVID-19 illness prior to exposure and provide early treatment if administered soon after infection, according to a study in mice led by Cornell researchers. Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti Applied treatment regimens aimed to explore differences regarding viral carriage upon treatment with azelastine compared to placebo. The analysis of sum symptom scores showed that the study population (ITT analysis set) suffered from moderate symptoms (mean valuesSD: 38.5810.04) on day 1 of the study (supplementary Table S5). Patients aged 18 to 60years were eligible to participate if tested positive for SARS-CoV-2 in a Corona test centre by PCR test within 48h prior to inclusion and had to quarantine at home due to instructions of the local health authority. Scientists are working on fast-acting nasal sprays to block coronavirus infections but formulating the sprays is a challenge. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385. The spritz developed by Moscona's team is one of a raft of proposed nasal sprays to prevent SARS-CoV-2 infection. Use the Previous and Next buttons to navigate the slides or the slide controller buttons at the end to navigate through each slide. PubMed Anticipating a drop-out rate of 20%, the aim was to randomize 90 patients in total (30 patients per treatment group) to result in 23 patients per treatment group completing the study and being eligible for analysis. Multinomial regression analysis was done to 26 determine the association between nasal carriage of Bacillus and COVID-19 severity after 27 adjusting for age, sex, and co-morbidity status. Viral load and disease severity in COVID-19. A final safety follow-up and assessment of the patient status (WHO scale) by phone call was done on day 60 (V9) for all patients. Overall, the current results are encouraging; however, further studies should be carried out to strengthen the findings, and treatment should be extended to other age and risk groups and cover individuals with different levels of symptom severity. was responsible for the patient disposition. Now, researchers at Swansea University will test it against Covid-19. J.P.K. Of note, 30 (non-related) adverse events in 13 patients (7 patients with 16 events in the 0.1% azelastine, 2 patients with 4 events in the 0.02% azelastine, and 4 patients with 10 events in the placebo group) were still ongoing at the final safety follow up on day 60. June 16, 2022, U.S. Department of Health and Human Services, The researchers first tried one dose a day for seven days, starting a day before SARS-CoV-2 infection. Odhar, H. A. et al. 27, 790792. Secondary endpoints included the assessment of symptoms, patient status (using a 11-category ordinal score as proposed by the WHO11), body temperature and blood oxygen saturation, quality of life (reported in the SF-36 generic quality of life questionnaires) and safety (adverse events, including worsening of patient status/symptoms) over time. 62, 50937, Cologne, Germany, CEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria, Eszter Nagy,Valria Szijrt&Gbor Nagy, Department of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Dr.-Bohr-Gasse 9, 1030, Vienna, Austria, Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str.